Emergent BioSolutions ya ce a ranar Alhamis Hukumar Abinci da Magunguna ta Amurka ta amince da rigakafin cutar anthrax don amfani da manya masu shekaru 18 zuwa 65.
An yarda da maganin, Cyfendus, don amfani da shi bayan da ake zargi ko tabbatar da kamuwa da wani nau’in ƙwayoyin cuta kuma dole ne a yi shi tare da magungunan kashe qwari.
Anthrax cuta ce mai saurin kamuwa da cuta wacce ke haifar da kamuwa da kwayar cutar Bacillus anthracis. Kwayoyin cuta sun fi shafar dabbobi masu kofato irin su awaki, amma mutanen da suka yi mu’amala da spores suma suna iya kamuwa da cutar.
Emergent yana isar da Cyfendus zuwa Ma’aikatar Lafiya da Ayyukan Jama’a ta Amurka tun daga 2019, a ƙarƙashin matsayin izinin amfani na gaggawa, kuma za ta ci gaba da yin aiki tare da gwamnatin Amurka don canzawa zuwa sayayya bayan amincewa, in ji kamfanin.
Emergent BioSolutions ya ce a ranar Alhamis Hukumar Abinci da Magunguna ta Amurka ta amince da rigakafin cutar anthrax don amfani da manya masu shekaru 18 zuwa 65.
An yarda da maganin, Cyfendus, don amfani da shi bayan da ake zargi ko tabbatar da kamuwa da wani nau’in ƙwayoyin cuta kuma dole ne a yi shi tare da magungunan kashe qwari.
Anthrax cuta ce mai saurin kamuwa da cuta wacce ke haifar da kamuwa da kwayar cutar Bacillus anthracis. Kwayoyin cuta sun fi shafar dabbobi masu kofato irin su awaki, amma mutanen da suka yi mu’amala da spores suma suna iya kamuwa da cutar.
Emergent yana isar da Cyfendus zuwa Ma’aikatar Lafiya da Ayyukan Jama’a ta Amurka tun daga 2019, a ƙarƙashin matsayin izinin amfani na gaggawa, kuma za ta ci gaba da yin aiki tare da gwamnatin Amurka kafin samun amincewar sayowa bayan amincewa, in ji kamfanin.
Reuters/L.N
Leave a Reply